Serono Ovidrel
Executive Summary
Filing for approval of the recombinant human chorionic gonadotropin is expected in both the U.S. and Europe by the end of the year, VP-Investor Relations & Scientific Affairs Andrew Galazka, MD, told the Warburg Dillon Read Conference Sept. 29. Phase III studies were completed in the second quarter (1"The Pink Sheet" Oct. 11, p. 22)